Merck & Co., Inc. (MRK) Q3 2026 Earnings Call

Concluded Oct 29, 2026

Oct 29, 2026

Executive readout · one minute

What the filings say

8-K earnings release · filed Oct 29, 2026: Merck & Co., Inc. reported third-quarter 2026 sales of $18.1 billion (5% Growth; 4% Growth ex-FX), GAAP EPS of $2.04 and non-GAAP EPS of $2.49. It raised full-year sales outlook to $66.8 billion–$67.3 billion and non-GAAP EPS outlook to $2.77–$2.82.

The audio replay and transcript follow the call.

Forward guidance

6 guided metrics

Management's latest ranges and targets are included below.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Open the source you need; every reader stays inside this workspace.

Presentation 28 pages 8-K earnings release Filed Oct 29, 2026 Company webcastOpen the original investor-relations page

From the 8-K filed Oct 29, 2026.

Metric	Period	Guided	Basis
Sales table Raised Full Year 2026	Full Year 2026	$66.8B – $67.3B	—
Non-GAAP Gross margin table Maintained Full Year 2026	Full Year 2026	81%	Non-GAAP
Non-GAAP Operating expenses table Raised Full Year 2026	Full Year 2026	$42.4B – $42.9B	Non-GAAP
Non-GAAP Other (income) expense, net table Maintained Full Year 2026	Full Year 2026	$1.4B	Non-GAAP
Non-GAAP EPS table Raised Full Year 2026	Full Year 2026	$2.77 – $2.82	Non-GAAP
Non-GAAP Effective income tax rate table Lowered Full Year 2026	Full Year 2026	32% – 33%	Non-GAAP